信达生物(01801)：国药监批准达伯舒® (信迪利单抗注射液)联合达攸同® (贝伐珠单抗注射液)用于治疗一线肝癌

“特别声明：以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布，本平台仅提供信息存储空间服务。

Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”